source
- Most new drugs are still too costly at launch, ICER saysA new analysis from the non-profit group found that net launch prices for new medicines spiked significantly between 2022 and 2025, and the majority were well above its cost-effectiveness guidelines.BioPharma Dive · 1h ago↗ source
- Industry at a ‘turning point’ with growth dominated by commercial leaders: EY reportA new report has found that in 2025 through the first half of 2026, innovation increased dealmaking and R&D investment, AI heavily influenced the future of value creation, and that industry growth…Fierce Biotech · 12h ago↗ source
- Roche signs $15 billion ADC partnership with China's Hansoh, offering $400 million upfrontRoche announced a licensing agreement with Hansoh Pharmaceutical to develop a broad portfolio of antibody-drug conjugates (ADCs).\n\nThe deal includes an upfront cash payment of $400 million and a…